Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 6 | Arthritis Research & Therapy

Figure 6

From: NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor

Figure 6

Effect of dehydroxymethylepoxyquinomicin on NF-κB activation and NFATc1 expression in joints of collagen-induced arthritis. Fresh frozen sections of each ankle joint were double-stained: (a, d, g) with FITC-labeled antibody to an activated form of the p65 subunit of NF-κB, and (b, e, h) with phycoerythrin-labeled antibody to NFATc1. (c, f, i) Transmission microscopy images of the same slides to show the articular structure. First row, a typical joint of an arthritic mouse treated with vehicle alone (a-c). Second row, a typical joint of an arthritic mouse treated with dehydroxymethylepoxyquinomicin (d-f). Third row, a joint of an age-matched normal mouse (g-i). White arrow (a), staining by anti-NF-κB p65 antibody; blue arrow (b), staining by anti-NFATc1 antibody of the cells along the inner surfaces of bone lacunae.

Back to article page